Prime Medicine, Inc./$PRME
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Ticker
$PRME
Sector
Primary listing
Employees
146
Headquarters
Website
PRME Metrics
BasicAdvanced
$717M
-
-$1.35
2.58
-
Price and volume
Market cap
$717M
Beta
2.58
52-week high
$6.94
52-week low
$1.11
Average daily volume
2.9M
Financial strength
Current ratio
4.841
Quick ratio
4.745
Long term debt to equity
89.594
Total debt to equity
96.326
Profitability
EBITDA (TTM)
-201.029
Gross margin (TTM)
-3,367.96%
Net profit margin (TTM)
-4,342.44%
Operating margin (TTM)
-4,498.06%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-40.68%
Return on equity (TTM)
-146.81%
Valuation
Price to revenue (TTM)
130.07
Price to book
5.93
Price to tangible book (TTM)
5.93
Price to free cash flow (TTM)
-3.606
Free cash flow yield (TTM)
-27.73%
Free cash flow per share (TTM)
-1.123
Growth
Revenue change (TTM)
55.28%
Earnings per share change (TTM)
-18.13%
3-year earnings per share growth (CAGR)
-31.41%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prime Medicine, Inc. stock?
Prime Medicine, Inc. (PRME) has a market cap of $717M as of March 11, 2026.
What is the P/E ratio for Prime Medicine, Inc. stock?
The price to earnings (P/E) ratio for Prime Medicine, Inc. (PRME) stock is 0 as of March 11, 2026.
Does Prime Medicine, Inc. stock pay dividends?
No, Prime Medicine, Inc. (PRME) stock does not pay dividends to its shareholders as of March 11, 2026.
When is the next Prime Medicine, Inc. dividend payment date?
Prime Medicine, Inc. (PRME) stock does not pay dividends to its shareholders.
What is the beta indicator for Prime Medicine, Inc.?
Prime Medicine, Inc. (PRME) has a beta rating of 2.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.